The 16th Annual Suzhou Cell Industry Conference, a highly anticipated event in the field, was successfully held from November 28 to 29, 2023, at the Shangri-La Hotel in Suzhou. This conference gathered authoritative experts in cell biology, industry leaders, and numerous professionals interested in the development of the cell industry from both domestic and international arenas. Together, they discussed cutting-edge topics such as cell and gene therapy (CGT), organoids, exosomes, stem cells, and immune cells, plotting a path for innovative development in the cell industry.
As a leading brand in the entire cell industry chain service, Zhejiang Jinno Life Health Holding Group Co., Ltd. (shortened as "Jinno Bio") made an appearance at this grand event with its seven wholly-owned subsidiaries. Since its establishment in 2002, Jinno Bio has consistently adhered to the corporate spirit of "innovation and beyond," focusing on research and application in areas such as cell culture reagents, consumables, medical devices, organoids, cell storage, cell and gene testing, and cell therapy drug development within the greater health industry chain, aiming to provide superior solutions for human health.
GENOM BIO's Highlighted Presence
At this gathering of industry wisdom, GENOM BIO showcased its latest R&D achievements under the theme of "innovation and beyond," becoming one of the highlights of the exhibition. GENOM BIO has always been committed to technological innovation and product quality improvement. For this participation, GENOM BIO presented its latest research results and innovative products, including high-quality fetal bovine serum, self-developed matrix gel, efficient and stable MSC serum-free cell culture medium, advanced cell storage technology, and precise cell and gene testing services. The introduction of these products not only demonstrated GENOM BIO's deep accumulation in R&D but also reflected the company's keen insight into market demand.
In-depth Exchanges and Opportunities for Cooperation
During the exhibition, GENOM BIO's booth attracted a steady stream of visitors, engaging in lively exchanges with many professionals. Whether researchers or business partners, there was a strong interest in GENOM BIO's products, and many expressed wishes for further cooperation. This is not only recognition of GENOM BIO's current achievements but also a beautiful anticipation of future cooperative prospects.
Industry Trends and Policy Directions
Notably, the timing of this conference coincided with Jiangsu Province's implementation of the "Jiangsu Province Action Plan for Strengthening Basic Research." This plan underscores the importance of strengthening basic research for enhancing independent scientific and technological innovation capabilities and clearly indicates that the government will increase support for precise stem cell research and major disease prevention and treatment research. This policy orientation undoubtedly provides a broader space for development for many cell biotechnology companies, including GENOM BIO.
Conclusion
With the rapid development of life sciences, cell and gene therapy are gradually becoming one of the key technologies that can change the fate of human health. As an industry leader, GENOM BIO will continue to uphold the spirit of "innovation and beyond," constantly exploring unknown fields and contributing to the promotion of high-quality development in the cell industry.